Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 68 publications
Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks.
Journal: Dermatology and therapy
Published: February 03, 2026
Vixarelimab in Patients With Prurigo Nodularis: A Randomized Clinical Trial.
Journal: JAMA dermatology
Published: December 17, 2025
Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials.
Journal: Acta dermato-venereologica
Published: November 04, 2025
Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK Analysis.
Journal: Dermatology and therapy
Published: October 16, 2025
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials.
Journal: Lancet (London, England)
Published: August 08, 2025
Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE study.
Journal: Journal of the American Academy of Dermatology
Published: June 27, 2025
Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 years.
Journal: Skin health and disease
Published: December 03, 2024
Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials.
Journal: Dermatology and therapy
Published: November 27, 2024
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial.
Journal: JAMA dermatology
Published: November 27, 2024
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials.
Journal: JAMA dermatology
Published: November 27, 2024
Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children.
Journal: Dermatology and therapy
Published: October 31, 2024
Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: August 23, 2024
Last Updated: 09/26/2026